Travere Therapeutics' FILSPARI Skyrockets in IgA, FSGS on Horizon

Travere Therapeutics had a breakthrough year in 2022 with their drug FILSPARI, significantly impacting IgA nephropathy treatment. The company experienced record demand, with $132 million in sales in Q4 alone, totaling $410.5 million for the year, a 144% increase. Despite new competitors, FILSPARIs strong commercial performance is evident. The FSGS push has been delayed to April 13, 2023, due to additional FDA requests, but leadership remains confident in FILSPARIs data. Physicians are increasingly using FILSPARI as a non-immunosuppressive option, with positive patient feedback. The company ended the year with $322.8 million in cash, bolstered by milestones. The pipeline is also progressing, with pegtibatinase resuming phase three trials for classical homocystinuria. Travere is poised for robust FILSPARI growth, potential FSGS launch, and pegtibatinases contribution, balancing execution and patient needs for the long term. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/0da52c6381c0508b